Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
522 results about "Benzimidazole derivative" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
This class of worm medicine has been used for decades, and remain a fairly common treatment in many cases because of their efficacy. Benzimidazole derivatives are so named because they are derived from a single compound, known as benzimidazole.
Benzimidazole derivatives and their use as KDR kinase protein inhibitors
The invention discloses and claims benzimidazole compounds of formula (I): wherein X is C—R2; Y is C—R2 or C—R3; W and Z are each C—R3; R1 is an optionally substituted aryl, heteroaryl or a saturated 5- or 6-membered monocyclic heterocyclic radical or a bicyclic heterocyclic radical; and A5 is H or alkyl; or a stereoisomer, a racemate, an enantiomer or a diastereoisomer of said compound of formula (I) or a pharmaceutically acceptable salt thereof; the use of compounds of formula (I) for the treatment of a disorder of proliferation of blood vessels, uncontrolled angiogenesis, a fibrotic disorder, a disorder of proliferation of mesangial cells, a metabolic disorder, allergy, asthma, thrombosis, a disease of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration, solid tumors and cancers, pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents and pharmaceutical compositions comprising a compound of formula (I) and one or more. antimitiotic agents.
Owner:AVENTIS PHARMA SA (US)
Novel benzimidazole derivatives
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Linked dibenzimidazole derivatives
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Benzimidazole derivatives
Owner:ENANTA PHARM INC
N3 alkylated benzimidazole derivatives as MEK inhibitors
ActiveUS7235537B2Useful in treatmentBiocideOrganic active ingredientsBenzimidazole derivativeDisease
Disclosed are compounds of the formula Iand pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
Owner:ASTRAZENECA AB +1
Light emitting element, light emitting device having the same and method for manufacturing the same
ActiveUS20080023724A1High refractive indexHigh color puritySolid-state devicesOrganic semiconductor devicesBenzimidazole derivativeRefractive index
A light emitting element comprises a first electrode, a second electrode configured to transmitting light, an organic layer arranged between the first and the second electrodes, comprising a light emitting layer, and a capping layer arranged on the second electrode and made of a material with a higher refractive index than the refractive index of the material constituting the second electrode. The material constituting the capping layer comprises at least one selected from the group consisting of triarylamine derivative, carbazole derivative, benzimidazole derivative and triazole derivative.
Owner:LG DISPLAY CO LTD
Benzimidazole derivatives, preparation method and medicinal use thereof
ActiveCN103709154AEnhanced antihypertensive activityEnhance antihypertensive effectOrganic active ingredientsOrganic chemistryBenzimidazole derivativeLiver and kidney
The invention belongs to the technical field of the pharmaceutical chemistry, and concretely discloses benzimidazole derivatives, and a preparation method and a medicinal use thereof. The benzimidazole derivatives comprise ligustrazine and NO donor derivatives, and the benzimidazole derivatives can rapidly release ligustrazine or NO in vivo, so there is an effective synergistic effect between the benzimidazole derivatives and azilsartan, thereby the benzimidazole derivatives enhances the antihypertension effect, reduces untoward effects, has an ideal protection effect on the liver and kidney of a patient, and fills a gap in the prior art.
Owner:WUHAN LL SCI & TECH DEV
Benzimidazole derivatives and use thereof
The invention provides compounds that are useful as sodium channel blockers. In one aspect, the invention provides compounds of Formula I:and pharmaceutically acceptable salts, solvates, hydrates, or diastereomers thereof, wherein W1, W2, W3, W4, U, G, m, R1, and R2 are defined in the disclosure. In certain embodiments, the invention provides compounds of Formulae II to V as set forth supra. The invention also provides the use of compounds of any of the above discussed formulae to treat a disorder responsive to blockade of sodium channels. In one embodiment, Compounds of the Invention are useful for treating pain.
Owner:PURDUE PHARMA LP
Benzimidazole derivatives as modulators of IgE
Owner:AVANIR PHARMA
Benzimidazole derivatives
ActiveUS20090005416A1Ease of preparation and detectabilityGood metabolic stabilityBiocideOrganic chemistryBenzimidazole derivativePharmaceutical medicine
The present invention relates to a compound of the Formula Ior a pharmaceutically acceptable salt thereof, wherein R1, R2, R3A, R3B, R4, R5, X, m, and n are as defined herein. Such novel benzamidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
Owner:PFIZER INC
N-methyl-substituted benzamidazoles
Owner:WARNER-LAMBERT CO
Benzimidazole derivates: preparation and pharmaceutical applications
InactiveUS20070043043A1Low toxicityPotent anti-proliferative activityBiocideSenses disorderBenzimidazole derivativeDisease cause
The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC).
Owner:MEI PHARM INC
Parenteral and oral formulations of benzimidazoles
ActiveUS20090048322A1Good treatment effectImprove drug solubilityOrganic active ingredientsBiocideBenzimidazole derivativeMebendazole
Provided herein are drug delivery systems, such as self-nanoemulsifying drug delivery systems, self-emulsifying drug delivery systems and parenteral microemulsion formulations, suitable for parenteral or oral delivery to a subject. The drug delivery systems may comprise a benzimidazole derivative, e.g., mebendazole, an oil, a surfactant, a cosurfactant and a dipolar aprotic solvent in a microemulsion formulation. Also provided are methods for improving the bioavailability of a benzimidazole derivative during treatment of a pathophysiological condition by using a formulation combining a particular emulsion droplet diameter and ratio of the surfactant:cosurfactant therein, for increasing concentration and retention of a benzimidazole derivative in the lung via a parenterally administerable microemulsion with droplet size of about 35 nm to less than 100 nm and for defining hemolytically safe microemulsions of a benzimidazole derivative during a therapeutic treatment via a parenterally administerable microemulsion with a surfactant:cosurfactant content by weight of about 6% to 48%.
Owner:UNIV HOUSTON SYST
Benzimidazole derivatives as modulators of IgE
InactiveUS20050075343A1BiocideCarbohydrate active ingredientsBenzimidazole derivativeBenzimidazole analog
This invention relates to a family of benzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy, asthma, or any diseases where IgE is pathogenic.
Owner:SIRCAR JAGADISH C +3
N-methyl-substituted benzamidazoles
Owner:WARNER LAMBERT CO LLC
Indole derivatives or benzimidazole derivatives for modulating IkB kinase
ActiveUS20050197353A1Efficient productionBiocideNervous disorderBenzimidazole derivativeKinase activity
The present invention relates to indole derivatives or benzimidazole derivatives, to processes for preparing such compounds, to pharmaceutical compositions comprising such compounds, and methods for the prophylaxis and therapy of a disease associated with an increased activity of IκB kinase comprising administering such compounds.
Owner:SANOFI AVENTIS DEUT GMBH
Organic electroluminescence device
ActiveUS20100301312A1Improve efficiencyLong life-timeOrganic chemistryNanoinformaticsBenzimidazole derivativeElectron injection
An organic electroluminescence device including: an anode (10), a cathode (70), an emitting layer (40) including an organic compound, which is between the anode (10) and the cathode (70), two or more layers arranged in a hole injection and transport region which is between the anode (10) and the emitting layer (40), and one or more layers arranged in an electron injection and transport region which is between the emitting layer (40) and the cathode (70), wherein a layer in the hole injection and transport region, which is in contact with the emitting layer (40), includes an aromatic amine derivative having a carbazole skeleton, one of the layers other than the layer in contact with the emitting layer (40) in the hole injection and transport region includes one or more materials selected from the group consisting of thiophene derivatives, tricyclic or more cyclic fused aromatic derivatives, amine derivatives excluding the compound represented by the following formula (A), conductive polymers, CFx, CuPc, transition metal oxides, fullerenes and acceptor materials, and a layer in the electron injection and transport region includes a benzimidazole derivative.
Owner:IDEMITSU KOSAN CO LTD
Carboxyl- or hydroxyl-substituted benzimidazole derivatives
InactiveUS20090163552A1Useful in treatmentHigh triglycerideBiocideNervous disorderBenzimidazole derivativeMedicinal chemistry
This invention relates to novel carboxyl- or hydroxyl-substituted benzimidazole derivatives of formula (I)wherein R1 to R6 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to FXR and can be used as medicaments.
Owner:F HOFFMANN LA ROCHE & CO AG
Rubber composition and pneumatic tire made therefrom
InactiveUS20050176858A1Improve grip performanceImprove gripSpecial tyresBenzimidazole derivativeProduction rate
A rubber composition comprising 100 parts by weight of a rubber ingredient comprising natural rubber and / or a synthetic rubber, 0.1 to 50 parts by weight of at least one nitrogenous compound selected among benzimidazole derivatives having a specific structure and hydrazide derivatives having a specific structure, and 0.1 to 50 parts by weight of a protonic acid; and a pneumatic tire including a member formed from this rubber composition. The rubber composition enables excellent gripping performance while attaining intact productivity. The pneumatic tire produced from this rubber composition, in particular, the tire whose tread has been formed from the composition, has significantly improved gripping performance in high-speed driving, etc.
Owner:BRIDGESTONE CORP +1
Synthesis and Anti-proliferative effect of benzimidazole derivatives
This invention provides for compounds, compositions, and methods that involve anti-proliferative and anti-neoplastic activity in cancer cells. In particular, a series of benzimidazole, purine, imidazopyridine, and imidazopyrizine compounds having selected substitution patterns are disclosed, and the activity of various subject compounds is demonstrated.
Owner:SPELMAN COLLEGE
Benzimidazole derivatives and their use as kdr kinase protein inhibitors
InactiveUS20080125418A1Inhibit cell proliferationGood treatment effectBiocideSenses disorderDiseaseNervous system
Owner:AVENTIS PHARMA SA
Benzimidazole derivatives
InactiveUS7125877B2High selectivityExcellent antagonismGroup 4/14 element organic compoundsBiocideBenzimidazole derivativeHypotension shock
This invention provides compounds which are represented by a general formula [I][in which X stands for hydrogen or halogen; B stands for halogen, cyano or optionally fluorine-substituted lower alkyl; D stands for a 3–10 membered aliphatic nitrogen-containing heterocyclic group; R3, R4 and R5 may be same or different, and each stands for hydrogen, lower alkyl optionally having substituent group(s) and the like; and a is 0 or 1]. These compounds exhibit high affinity to nociceptin receptors and whereby inhibit actions of nociceptin, and are useful as an analgesic, antiobestic, agent for ameliorating brain function, treating agents for Alzheimer's disease and dementia, and therapeutic agents for schizophrenia, neurodegenerative diseases, depression, diabetes insipidus, polyuria, hypotension and the like.
Owner:MSD KK
Pharmaceutical formulations comprising substituted benzimidazole derivatives
InactiveUS20120058194A1Increasing duration of timeImprove stabilityBiocidePowder deliveryBenzimidazole derivativeGastro-esophageal reflux disease
Stabilized substituted benzimidazole modified release pharmaceutical formulations with at least two drug-containing fractions, wherein the release from a first fraction precedes the release from a second fraction, pharmaceutical excipients, processes for preparing the stable formulations, packaging therefor, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease.
Owner:DR REDDYS LAB LTD +1
Benzimidazole derivative
InactiveUS20100190826A1Suppress intracrine androgen synthesisBiocideOrganic chemistryDiseaseBenzimidazole derivative
Owner:ASTELLAS PHARMA INC
Organic electroluminescent device and display apparatus
ActiveUS20100252823A1Electron injection can be reducedImprove electron injection performanceSolid-state devicesSemiconductor/solid-state device manufacturingBenzimidazole derivativeAryl
An organic electroluminescent device includes an anode; a cathode; an organic layer including a light-emitting layer and disposed between the anode and the cathode; and an electron transport layer constituting the organic layer, disposed between the cathode and the light-emitting layer, and having a stacked structure including a layer containing a benzimidazole derivative and a layer containing a dibenzimidazole derivative represented by general formula (1):wherein Y1 to Y8 each represent a substituted or unsubstituted aryl group having 6 to 60 carbon atoms, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted pyridyl group, a substituted or unsubstituted quinolyl group, a substituted or unsubstituted alkyl group having 1 to 20 carbon atoms, a substituted or unsubstituted alkoxy group having 1 to 20 carbon atoms, or a substituted or unsubstituted aliphatic cyclic group, and Y7 and Y8 may form a ring through a linking group.
Owner:JOLED INC
Stable oral formulation containing benzimidazole derivative
An enteric formulation containing at least one benzimidazole derivative, said formulation comprising: a core containing at least one benzimidazole derivative and at least one lipophilic antioxidant, and an enteric envelope protecting the core at least at a pH of 3 to 5, preferably at a pH of 1 to 5.
Owner:GALEPHAR M F
Novel benzimidazole derivatives
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
N3 alkylated benzimidazole derivatives as MEk inhibitors
ActiveUS20050143438A1Enhanced inhibitory effectGrowth inhibitionOrganic active ingredientsBiocideDiseaseBenzimidazole derivative
Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
Owner:ARRAY BIOPHARMA +1
Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
Compounds of formula (I) are inhibitors of PDK1 and CHK1 activity, and of use in the treatment of cancer and autoimmune disorders (I): wherein R2 is a radical of formula R7—(CH2)n−, or a radical of formula -Alk-N(—R5)—R9 wherein n is 0, 1, 2 or 3 and Alk is C1-C6 alkylene; R7 is (i) a heterocyclic ring of 5 or 6 ring atoms coupled via a ring carbon wherein the sole heteroatom is nitrogen, optionally substituted by C1-C6 alkyl or aryl C1-C6 alkyl, (ii) 1-aza-bicyclo[2.2.2]oct-3-yl, or (iii) 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl; R8 and R9 are independently selected from hydrogen or C1-C3 alkyl; and the remaining substituents are as defined in the claims.
Owner:VERNALIS RES
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com